Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill
Chief Operating Officer, James Hill
Source: The Market Herald
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Singular Health Group (SHG) teams up with CSIRO and Osteopore (OSX) for an artifical intelligence (AI) based tool to make patient-specific 3D cranial implants
  • The company has received $50,000 from CSIRO’s kick-start program to undertake research with the national science agency
  • The program will focus on the development of an AI based tool to automatically generate cranial implants for craniotomies from CT scans
  • Results from the program will be checked by Singular with a dataset provided by Osteopore (OSX)
  • On the market today, Singular was up 20 per cent and is trading at 21 cents per share

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial implants.

The company has received $50,000 from CSIRO’s kick-start program to undertake research with the national science agency.

The program will focus on the development of an AI-based tool to automatically generate cranial implants for craniotomies from CT scans.

Results from the program will be checked by Singular with a dataset provided by Osteopore (OSX), as part of a recently signed memorandum of understanding (MOU) agreement.

The MOU also includes a comparative study between the existing cranial implant to the new process.

In addition to the $50,000 investment which is being dollar-matched by the CSIRO KickStart program, Singular’s contribution to the MOU includes utilising its 3Dicom Surgical as the software platform for the tool.

Singular Health’s Managing Director, Thomas Hanly, said this project marks an exciting step for the company.

“Too often, advances in medical technology are made without the input of peers to focus on commercial priorities,” Mr Hanly said.

“Working with Osteopore ensures our work and results will be objectively compared with existing techniques and paves the way for future collaborations and commercialisation opportunities. In this space alone, according to Cetas Healthcare (2020), there are an estimated 1.1 million cranial procedures per annum globally.”

On the market today, Singular was up 20 per cent and is trading at 21 cents per share at 1:45 pm AEDT.

SHG by the numbers
More From The Market Online
The Market Online Video

Listen: From the Wire – Paradigm Biopharma CEO and Founder Paul Rennie

From The Wire: Senior markets reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals chief executive officer…
Lung imaging concept

Biotech lung imaging darling 4DX Medical back at $2.20/sh on Miami U contract

4DX Medical has seen its price jump back to $2.20/sh, as its next-gen lung imaging scan…
Chuffed bloke

Race Oncology’s placement-at-a-premium rewarded as shares jump +8%

Race Oncology has completed its recent A$3.2M placement – something that shareholders on the HotCopper forums…

Effective as an IV drug, a gel, and now an inhaler – Recce’s R327 can’t stop winning

Recce flagship antibacertial and anti-infective drug R327 has in a model that shows the drug could…